What it is
PNC-27 is a synthetic peptide studied in preclinical cancer models for selective membrane disruption in tumor cells. Human protocol data are not established.
Evidence boundary
Preclinical / speculative. Do not present a human dosing schedule as established fact.
Trial evidence
No verified human trial found.
Preparation and measurement
Reconstitution: 30 mg vial + 3 mL BAC = 10 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 100 mcg | 1 U (0.01 mL) | Once daily | 700 mcg/week |
| Weeks 3–4 | 200 mcg | 2 U (0.02 mL) | Once daily | 1.4 mg/week |
| Weeks 5–8 | 300 mcg | 3 U (0.03 mL) | Once daily | 2.1 mg/week |
| Weeks 9–12 | 400 mcg | 4 U (0.04 mL) | Once daily | 2.8 mg/week |
| Weeks 13–16 (target) | 500 mcg | 5 U (0.05 mL) | Once daily | 3.5 mg/week |
Weeks 1–2 (titration)
- Dose
- 100 mcg
- Draw / measure
- 1 U (0.01 mL)
- Frequency
- Once daily
- Weekly total
- 700 mcg/week
Weeks 3–4
- Dose
- 200 mcg
- Draw / measure
- 2 U (0.02 mL)
- Frequency
- Once daily
- Weekly total
- 1.4 mg/week
Weeks 5–8
- Dose
- 300 mcg
- Draw / measure
- 3 U (0.03 mL)
- Frequency
- Once daily
- Weekly total
- 2.1 mg/week
Weeks 9–12
- Dose
- 400 mcg
- Draw / measure
- 4 U (0.04 mL)
- Frequency
- Once daily
- Weekly total
- 2.8 mg/week
Weeks 13–16 (target)
- Dose
- 500 mcg
- Draw / measure
- 5 U (0.05 mL)
- Frequency
- Once daily
- Weekly total
- 3.5 mg/week
Weekly totals apply only during the active phase.
Titration rules
- No automatic escalation is specified in the available source. Keep the stated dose fixed for the defined phase rather than inventing intermediate steps.
Cycle length and breaks
Use only the defined schedule window and reassess before extending it.
What to monitor
- Whether a source is actually human data
- Limited safety information
- Injection-site reactions
- Theoretical selectivity claims in preclinical models
Practical rules
- Do not frame preclinical cancer selectivity as human guidance.
- Rotate sites.
- Keep the interpretation separate from any real oncology treatment.